Tosaki A, Guillon J M, Koltai M, Braquet P
Institut Henri-Beaufour/IPSEN, Les Ulis, France.
Arch Mal Coeur Vaiss. 1989 Nov;82 Spec No 4:155-61.
The antiarrhythmic effects of cicletanine (CIC), a new antihypertensive drug, were studied on isolated hearts from SHR and WKY rats subjected to global normothermic ischaemia. The effects of CIC on variations in intracellular sodium concentration induced by ischaemia-reperfusion were measured. After a 14-day treatment with CIC in doses of 30 and 100 mg/kg/day, the results were as follows: in WKY rats the incidence of ventricular fibrillation (VF) was reduced from 91% in controls to 41% and 50% (p less than 0.05) and the incidence of ventricular tachycardia (VT) was reduced from 100% to 41% and 58% (p less than 0.05). In SHR rats the percentages of VF were 100% in controls and 17% (p less than 0.001) and 33% (p less than 0.01) respectively in treated animals. Similarly, the incidence of VT was reduced from 100% to 17% (p less than 0.001) and 25% (p less than 0.001) respectively. The effects of CIC were more pronounced on SHR rats than on WKY rats. CIC reduced the intracellular sodium accumulation induced by ischaemia and reperfusion. The antiarrhythmic activity of CIC seems to be correlated with its inhibitory activity on intracellular sodium accumulation.
研究了新型抗高血压药物西氯他宁（CIC）对遭受整体常温缺血的SHR和WKY大鼠离体心脏的抗心律失常作用。测量了CIC对缺血再灌注诱导的细胞内钠浓度变化的影响。以30和100mg/kg/天的剂量用CIC治疗14天后，结果如下：在WKY大鼠中，室颤（VF）发生率从对照组的91%降至41%和50%（p<0.05），室性心动过速（VT）发生率从100%降至41%和58%（p<0.05）。在SHR大鼠中，对照组的VF百分比为100%，治疗组动物分别为17%（p<0.001）和33%（p<0.01）。同样，VT发生率分别从100%降至17%（p<0.001）和25%（p<0.001）。CIC对SHR大鼠的作用比对WKY大鼠更明显。CIC减少了缺血和再灌注诱导的细胞内钠蓄积。CIC的抗心律失常活性似乎与其对细胞内钠蓄积的抑制活性相关。
